Measles, Rubella and Congenital Rubella Syndrome (CRS) Country Profile

Guyana

Pan American Health Organization

Introduction

The measles and rubella country profile aims to facilitate the analysis of data compiled in the last five years. This profile was only developed for those countries who officially reported vaccination coverage and case by case surveillance and laboratory data to the Pan American Health Organization (PAHO). There may be minor differences in the country profile if the country has updated data that was not reported to PAHO. The country profile will be automatically updated twice per year: at the end of April (surveillance data) and at the end of September (vaccination coverage data).

General Information

Table 1: Demographic data, 2022.

Demographic group	Population
1 year of age Total population	15,836 808,752

Table 2: Last endemic cases by year and disease.

Measles	Rubella	CRS
1991	1999	1998

Table 3: Vaccination schedule.

Vaccine	1st Dose	2nd Dose	MMR2 Year Introduced
MMR	12 mo	18 mo	2001

Table 4: Accumulation of susceptibles for measles and rubella.

Year of the	Vaccine	Age	Number	Coverage of the	Number of	Year of
last	used (M,	group	vaccinated	follow-up	susceptibles	next
follow-up	MR,	vacci-	(numera-	campaign	1-4 years of	cam-
campaign	MMR)	nated	tor)	(B/C)*100	age	paign
2019	MMR	1-59	NA	NA	NA	2022

Epidemiology and Quality of Surveillance

Figure 1: Distribution of suspected MR cases and notification rate at the national level, 2018-2022.




Table 5: Distribution of suspected MR cases and notification rate at the national level, 2018-2022.

	2018	2019	2020	2021	2022
Suspected MR cases	34	43	7	0	23
Suspected MR notification rate per 100,000 population	4.35	5.49	0.89	0	2.84

Figure 2: Distribution of suspected CRS cases and notification rate at the national level, 2018-2022.




Table 6: Distribution of suspected CRS cases and notification rate at the national level, 2018-2022.

	2018	2019	2020	2021	2022
Suspected CRS cases	0	4	12	0	0
Suspected CRS notification rate per 10,000 live births	0	2.74	8.41	0	0

Figure 3: Reported cases of measles and rubella by epidemiological week and final classification: confirmed, discarded and under investigation, 2018-2022.




Figure 4: Number of measles and rubella cases by epidemiological year pending final classification, 2018-2022.






Table 7: Reported cases of measles and rubella by epidemiological year and final classification, 2018-2022.

Classification	2018	2019	2020	2021	2022
Confirmed (Measles)	0	0	0	0	0
Confirmed (Rubella)	0	0	0	0	0
Pending	0	1	0	0	0
Discarded	34	42	7	0	23
Total	34	43	7	0	23

Figure 5: Distribution of reported measles and rubella cases and incidence rate by age group, 2018-2022.








Figure 7: Proportion of the 11 variables reported for adequate investigation indicator, 2022.




Table 8: Municipalities reporting measles and rubella suspected cases by year, 2018-2022.


of municipalities reporting suspected cases
77
54
8
NA
69

Laboratory Surveillance

Table 9: Criteria used to discard suspected measles and rubella cases by year, 2018-2022.

Year No. of suspected cases reported			Criteria for discarding		No. of cases discarded by other differential diagnosis						
	No. of discarded cases	IgM Negative	No data	Others	Vaccine reaction	Dengue	Parvo virus	Herpes 6	Allergic reaction	Others	
2018	34	34	31	0	3	2	0	0	0	0	1
2019	43	42	40	0	2	2	0	0	0	0	0
2020	7	7	7	0	0	0	0	0	0	0	0
2022	23	23	23	0	0	0	0	0	0	0	0

Figure 8: Distribution of discarded measles and rubella suspected cases by other differential diagnosis, 2018-2022.



Analysis of Vaccination Coverage and Population Cohorts

Figure 9: Coverage of the first dose of measles-mumps-rubella (MMR1) vaccine, number of doses administered, and number of children 1 year of age, 2018-2022.




Figure 10: Coverage of the second dose of measles-mumps-rubella (MMR2) vaccine, number of doses administered, and number of children 18 month(s) of age, 2018-2022.






Table 10: Vaccination coverage with first and second dose of measles-mumps-rubella (MMR1 and MMR2) vaccines by target population and administered doses, 2018-2022.

		MMR1			MMR2	
Year	Administered doses	Target population	Coverage	Administered doses	Target population	Coverage
2018	15,354	15,654	98	13,135	15,654	84
2019	15,048	15,313	98	14,118	15,313	92
2020	16,239	15,340	100	14,855	15,340	97
2021	14,492	15,283	95	12,751	15,283	83
2022	14,949	$14,\!524$	100	14,244	14,625	97

Figure 11: Subnational coverage of the first dose of measles-mumps-rubella (MMR1) vaccine and proportion of children aged 1 year, 2021











Figure 13: Proportion of children living in those municipalities for MMR1 vaccination coverage ranges, 2018-2022.








Figure 15: Proportion of children living in those municipalities for MMR2 vaccination coverage ranges, 2018-2022.




Table 11: Proportion of municipalities with MMR1 and MMR2 coverage ranges and proportion of children living in those municipalities, 2018-2022.

		MMR1		MN	IR2
Year	Coverage range (%)	MMR1	MMR2	MMR1	MMR2
2022	<80	0.0	0.0	0.0	0.0
2022	80-89	15.4	23.1	15.1	22.9
2022	90-94	7.7	7.7	9.6	9.6
2022	95-100	46.2	38.5	44.0	36.4
2022	>100	30.8	30.8	31.3	31.1
2021	< 80	23.0	38.0	NA	NA
2021	80-89	31.0	46.0	NA	NA
2021	90-94	23.0	8.0	NA	NA

$2021 \\ 2021$	95-100 >100	$23.0 \\ 0.0$	8.0 0.0	NA NA	NA NA
2019	<80	0.0	0.0	0.0	0.0
2019	80-89	0.0	38.5	0.0	36.6
2019	90-94	15.4	7.7	25.0	19.3
2019	95-100	53.8	38.5	56.4	32.1
2019	>100	30.8	15.4	18.6	12.1
2018	<80	0.0	15.4	0.0	6.3
2018	80-89	0.0	46.2	0.0	49.7
2018	90-94	15.4	30.8	18.5	39.4
2018	95-100	53.8	7.7	47.3	4.6
2018	>100	30.8	0.0	34.2	0.0

References

Section	Sources
General Information	 [1] United Nations, Department of Economic and Social Affairs, Population Division (2022). World Population Prospects 2022, Online Edition. [2] Country reports through the electronic PAHO-WHO/UNICEF Joint
Epidemiology and Quality of Surveillance	Reporting Form (eJRF). [3] Integrated Surveillance Information System (ISIS) and country reports to CIM/PAHO. [2] Country reports through the electronic PAHO-WHO/UNICEF Joint
Laboratory Surveillance	Reporting Form (eJRF). [3] Integrated Surveillance Information System (ISIS) and country reports to CIM/PAHO.
Analysis of Vaccination Coverage and Population Cohorts	[2] Country reports through the electronic PAHO-WHO/UNICEF Joint Reporting Form (eJRF).